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i n d i a n h e a r t j o u r n a l 6 4 ( 2 0 1 2 ) 6 1 4e6 1 9618in the outcomes among the hospitals with frequent use of
IABP for complex PCI versus hospitals with less use of IABP.
This registry has analysed data from more than 180,000
patients who underwent complex PCI with use of IABP in
about 19,000 (10.5%) procedures.
Although, believers of IABPmay have one or other criticism
for these trials but the fact remains that these are (especially
IABP SHOCK II) large randomised trials and they have failed to
show benefit of IABP use consistently. These results will have
impact on the IABP usage in the coming years and researchers
will have to look for new protocols/algorithms to decide about
the need for IABP in a particular patient. The only comforting
point for IABP use is that there were no IABP related compli-
cations. This will give IABP users some leverage to use it on
a case to case basis as it is not doing any harm.
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Objectives: The goal of this study was to compare angio-
graphic, intravascular imaging, and functional parameters, as
well as the clinical outcomes of patients treated with drug-
eluting balloon (DEB) plus bare-metal stent (BMS) versus
BMS versus drug-eluting stent (DES) for ST-segment elevated
acute myocardial infarction (STEMI).
Background: Concerns remain regarding the long-term
safety of DES in STEMI. DEB could provide an attractive
alternative in order to achieve potentially similar effective-
ness but limiting the long-term hazards related to late-
acquired stent malapposition and thus stent thrombosis.
Methods: In this randomized, international,2-center, single-
blinded, 3-arm study, STEMI patients were randomly assigned
to group A: BMS; group B: DEB plus BMS; or group C: DES after
successful thrombus aspiration. The primary endpoint was 6-
month angiographic in-stent late-luminal loss. Secondary
endpoints were in-stent binary restenosis, major adverse
cardiac events (MACE: cardiac death, myocardial infarction,
target vessel revascularization). In a subgroup of patients, stent
(mal) apposition (by optical coherence tomography) and endo-
thelial function (by acetylcholine infusion) was assessed.
Results: Overall, 150 patients were randomized. Procedural
success was achieved in 96.7%. In groups A, B, and C,
respectively, late-luminal loss was 0.74e0.57 mm,
0.64e0.56 mm, and 0.21e0.32 mm (pe0.01); binary restenosiswas 26.2%, 28.6%, and 4.7% (p e 0.01); and MACE rates were
23.5%, 20.0%, and 4.1% (p e 0.02), respectively. The median
percentage [25the75th interquartile range] of uncovered and
malapposed stent struts per lesion was 0 [0e0.35], 2.84
[0e6.63], and 5.21 [3.25e14.5] (pe 0.01). Significant paradoxical
vasoconstriction was seen in groups B and C.
Conclusions: In STEMI patients, DEB followed by BMS
implantation failed to show angiographic superiority to
BMS only. Angiographic results of DES were superior to both
BMS and DEB. Moreover, DEB before implantation induced
more uncovered and malapposed stent struts than BMS, but
less than after DES.
Perspective
The main findings of this randomized, multicentre study are:
1) DIOR DEB failed to demonstrate angiographic superiority
over BMS, with similar late-luminal loss and binary restenosis
rates; 2) DES showed significantly better angiographic and
clinical results compared with both DEB and BMS; and 3) DEB
had significantly more combined uncovered and malapposed
struts compared with BMS, but less compared with the DES
group.
DEB appeared to be an attractive option in the treatment of
STEMI in combination with a BMS because of the following
theoretical advantages: 1) homogeneous distribution of the
drug to the vessel wall, especially at the area of the culprit
plaque, whereas the DES delivers the drug only in the prox-
imity of its struts; 2) better angiographic results, and hence
less need for TLR; 3) less malapposition, with potentially less
stent thrombosis with respect to DES; 4) preservation of
endothelial function with respect to DES; and 5) possibly less
prone to the potential clinical consequences in case of short-
ened dual antiplatelet duration, or in patients incapable of
adhering to 12-month dual antiplatelet therapy. Notwith-
standing these potential advantages, the DEB used in this
study failed to prove superior angiographic outcomes.
Moreover the percentage of uncovered and malapposed
struts as seen on OCT suggest that there is a drug effect
induced by DEB that shows morphological changes compared
with BMS alone. The DES group showed even more
pronounced morphological changes. These results may
suggest that the DEB did induce some effects on neointimal
proliferation as demonstrated by OCT; however, they were
insufficient to cause enough inhibition of the process to
reduce late-luminal loss as compared with the BMS group.
Also, the acetylcholine testing findings in the present study
point toward a drug effect in DEB-treated patients. After
incremental acetylcholine infusions, paradoxical vasocon-
striction occurred in the DEB- and DES-treated patients, with
insignificantly more pronounced vasoconstriction in DEB
compared with DES. By contrast, endothelial function in the
BMS group was stable after incremental acetylcholine
concentrations.
Our opinion
Primary PCI with DES has been shown to be better than BMS in
reducing TLR without an increased risk of stent thrombosis in
i n d i a n h e a r t j o u rn a l 6 4 ( 2 0 1 2 ) 6 1 4e6 1 9 619large trials like the HORIZONS-AMI, TYPHOON and SESAMI
trials. However, concern remains of risk of late stent throm-
bosis because of stent malapposition, presence of the drug
polymer and long-term continuation of dual antiplatelet
therapy. It was precisely because of this reason that DEB was
being thought of as an alternative to DES, where we could get
the beneficial effects of the drug without exposure to drug
polymer or long-termantiplatelet therapy. Thiswas especially
true in the setting of STEMI. However, this trial proves it all
false and as mere hype. It shows using all latest technology
like OCT and acetylcholine testing that DEB with a BMS has
only the ill-effects of DES (stent malapposition and paradox-
ical vasoconstriction) without its beneficial effects (decreased
late-luminal loss and binary restenosis rate). Thus what we
actually achievewithDEB is notmore than BMS alone in termsof restenosis and TLR rates plus the ill-effects of DES that too
at an increased cost. This trial proves that newer technology
should not be blindly followed and DES are here to stay as the
first choice in primary PCI.
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